Paclitaxel Treatment Options

A collection of 2028 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

NCT03474107

Active Not Recruiting

The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemothera... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: UCI Chao Family Comprehensive Cancer Center, Orange, California +157 locations

UCI Chao Family Comprehensive Cancer Center, Orange, California

University of California, Sacramento, California

Innovative Clinical Research, Whittier, California

University of Colorado, Denver, Colorado

Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut

Sylvester Comprehensive Cancer Center, Miami, Florida

Florida Hospital, Orlando, Florida

Rush University Medical Center, Chicago, Illinois

Norton Cancer Institute, Louisville, Kentucky

Dana-Farber Cancer Institute, Boston, Massachusetts

Nebraska Cancer Specialists, Omaha, Nebraska

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Long Island Jewish Medical Center, Lake Success, New York

Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York

White Plains Hospital Center for Cancer Care - Oncology Site, White Plains, New York

Toledo Clinic Cancer Center, Toledo, Ohio

Providence Portland Med Center, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Lifespan Rhode Island Hospital, Providence, Rhode Island

Saint Francis Hospital, Greenville, South Carolina

HOPE Cancer Center of East Texas, Tyler, Texas

Benaroya Research Institute at Virginia Mason, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

Site AR54001, Buenos Aires, Not set

Site AU61006, Adelaide, Not set

Site AU61001, Miranda, Not set

Site AU61004, St. Leonards, Not set

Site AU61002, Sydney, Not set

Site AT43005, Linz, Not set

Site AT43001, Salzburg, Not set

Site AT43004, Wien, Not set

Site BE32011, Aalst, Not set

Site BE32007, Brussels, Not set

Site BE32013, Brussels, Not set

Site BE32010, Charleroi, Not set

Site BE32001, Gent, Not set

Site BE32008, Gent, Not set

Site BE32005, Hasselt, Not set

Site BE32003, Leuven, Not set

Site BE32009, Liège, Not set

Site CA15015, Calgary, Not set

Site CA15012, Edmonton, Not set

Site CA15014, London, Not set

Site CA15002, Montreal, Not set

Site CA15007, Montreal, Not set

Site CA15011, Oshawa, Not set

Site CA15004, Quebec, Not set

Site CA15008, Saskatoon, Not set

Site CA15001, Sherbrooke, Not set

Site CA15005, Toronto, Not set

Site CA15013, Vancouver, Not set

Site DK45003, Aalborg, Not set

Site DK45004, Copenhagen, Not set

Site DK45001, Herlev, Not set

Site FR33021, Besancon, Not set

Site FR33009, Bordeaux, Not set

Site FR33018, Bordeaux, Not set

Site FR33001, Brest, Not set

Site FR33016, Caen, Not set

Site FR33015, Lyon, Not set

Site FR33014, Marseille, Not set

Site FR33003, Nice, Not set

Site FR33022, Paris, Not set

Site FR33005, Pierre-Bénite, Not set

Site FR33004, Saint-Mande, Not set

Site FR33002, Strasbourg, Not set

Site FR33019, Toulouse, Not set

Site FR33006, Villejuif, Not set

Site DE49011, Essen, Not set

Site DE49008, Heidelberg, Not set

Site DE49010, Münster, Not set

Site DE49003, Tübingen, Not set

Site DE49009, Würzburg, Not set

Site IT39008, Arezzo, Not set

Site IT39019, Cremona, Not set

Site IT39010, Milan, Not set

Site IT39025, Modena, Not set

Site IT39013, Pisa, Not set

Site IT39014, Reggio Emilia, Not set

Site IT39004, Terni, Not set

Site JP81010, Hirosaki, Aomori

Site JP81014, Kashiwa, Chiba

Site JP81007, Sapporo, Hokkaido

Site JP81026, Sapporo, Hokkaido

Site JP81020, Tsukuba, Ibaraki

Site JP81018, Morioka, Iwate

Site JP81009, Kita-gun, Kagawa

Site JP81002, Yokohama, Kanagawa

Site JP81005, Sendai, Miyagi

Site JP81016, Osakasayama, Osaka

Site JP81024, Takatsuki, Osaka

Site JP81008, Bunkyo-ku, Tokyo

Site JP81012, Koto-ku, Tokyo

Site JP81013, Shinjuku-ku, Tokyo

Site JP81011, Ube, Yamaguchi

Site JP81015, Chiba, Not set

Site JP81019, Fukuoka, Not set

Site JP81023, Fukuoka, Not set

Site JP81004, Hiroshima, Not set

Site JP81001, Kyoto, Not set

Site JP81017, Niigata, Not set

Site JP81003, Okayama, Not set

Site JP81022, Osaka, Not set

Site JP81021, Tokushima, Not set

Site JP81006, Toyama, Not set

Site KR82006, Daejeon, Not set

Site KR82007, Goyang-Si, Not set

Site KR82012, Hwasun-gun, Not set

Site KR82002, Incheon, Not set

Site KR82001, Seongnam-si, Not set

Site KR82003, Seoul, Not set

Site KR82004, Seoul, Not set

Site KR82008, Seoul, Not set

Site KR82009, Seoul, Not set

Site KR82010, Seoul, Not set

Site KR82005, Shin, Not set

Site NL31002, Amsterdam, Not set

Site NL31003, Amsterdam, Not set

Site NL31009, Nijmegen, Not set

Site NL31001, Tilburg, Not set

Site PT35105, Lisboa, Not set

Site PT35102, Lisbon, Not set

Site PT35106, Porto, Not set

Site RU70002, Ivanovo, Not set

Site RU70009, Obninsk, Not set

Site RU70005, Omsk, Not set

Site RU70015, Vologda, Not set

Site ES34010, Badajoz, Not set

Site ES34002, Badalona, Not set

Site ES34001, Barcelona, Not set

Site ES34012, Barcelona, Not set

Site ES34023, Barcelona, Not set

Site ES34014, Córdoba, Not set

Site ES34003, Madrid, Not set

Site ES34013, Madrid, Not set

Site ES34015, Madrid, Not set

Site ES34017, Madrid, Not set

Site ES34011, Manresa, Not set

Site ES34019, Pamplona, Not set

Site ES34005, Seville, Not set

Site ES34007, Valencia, Not set

Site ES34008, Valencia, Not set

Site CH41002, Bern, Not set

Site CH41001, Chur, Not set

Site TW88602, Kaohsiung, Not set

Site TW88605, Kaohsiung, Not set

Site TW88606, Taichung, Not set

Site TW88601, Tainan, Not set

Site TW88604, Taipei, Not set

Site TW88607, Taoyuan, Not set

Site GB44005, London, Not set

Site GB44006, London, Not set

Site GB44002, Sheffield, Not set

Site GB44011, Southampton, Not set

Site GB44013, Sutton, Not set

Site GB44004, Wirral, Not set

Conditions: Ureteral Cancer, Urothelial Cancer, Bladder Cancer

Learn More ›

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

NCT03816163

Active Not Recruiting

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor. Zolbetuximab is a potential treatment for people with pancreatic cancer. There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be treated with either zolbetuximab and chemotherapy or chemotherapy by itself. The study's main aims are to find a suitable dose of zolbetuximab to be used with chemotherapy in the second part of this study, to check if zolbetuximab and chemotherapy compared to chemotherapy by itself can improve the survival of people with pancreatic cancer, and to check the safety of zolbetuximab when given with chemotherapy and how well people cope with medical problems during the study. Adults with metastatic pancreatic cancer can take part. Their cancer is metastatic, has the CLDN18.2 marker in a tumor sample and has not previously been treated with chemotherapy. Metastatic means the cancer has spread to other parts of the body. People cannot take part are if they have recently had radiotherapy and have not recovered, need to take medicines to suppress their immune system, have history of nervous system metastases from their pancreatic cancer, or they have other active cancers that need treatment. People who have a specific heart condition or infections also cannot take part. This study will be in 2 parts. Part 1 is called the Safety Lead-in Phase. Groups of people will receive 1 of 2 different doses of zolbetuximab: a lower dose or a higher dose, both together with chemotherapy. A medical expert panel will check the results and decide the dose to use in Part 2. Part 2 is called the Randomization Phase. People will be put in 1 of 2 groups by chance and will be given different treatments either zolbetuximab and chemotherapy or chemotherapy by itself. The chance of receiving zolbetuximab and chemotherapy is twice as high as receiving chemotherapy by itself. In both parts of the study, zolbetuximab and chemotherapy or chemotherapy by itself will be given through a vein. This is called an infusion. Each treatment cycle is 4 weeks (28 days) long and people will have either 2 infusions of zolbetuximab and 3 infusions of chemotherapy or 3 infusions of chemotherapy by itself during each treatment cycle. People will visit the clinic on certain days during their treatment. The study doctors will check for any medical problems from zolbetuximab. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken before treatment if a previous sample is not available. People will have the option of giving a tumor sample after treatment has finished. People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: St. Joseph Heritage Medical Group, Fullerton, California +135 locations

St. Joseph Heritage Medical Group, Fullerton, California

TOI Clinical research, Whittier, California

Midstate Medical Center, Meriden, Connecticut

Lynn Cancer Institute, Boca Raton, Florida

Baptist Health, Miami, Florida

Cancer Treatment Centers of Atlanta, Newnan, Georgia

University of Illinois at Chicago, Chicago, Illinois

Norton Cancer Institute (NCI), Louisville, Kentucky

Ochsner Health System, New Orleans, Louisiana

David C Pratt Cancer Center, Creve Coeur, Missouri

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

Memorial Sloan Kettering Bergen, Montvale, New Jersey

Roswell Park Cancer Institute, Buffalo, New York

Memorial Sloan Kettering Commack, Commack, New York

Memorial Sloan Kettering Westchester, Harrison, New York

Northwell Health Cancer Institute, Lake Success, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Memorial Sloan Kettering Nassau, Uniondale, New York

Novant Health Presbyterian Medical Center, Charlotte, North Carolina

Novant Health, Winston-Salem, North Carolina

Houston Methodist Hospital, Houston, Texas

Utah Cancer Specialists, Salt Lake City, Utah

MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor, Washington

Vista Oncology, Olympia, Washington

Virginia Mason, Seattle, Washington

Site AU61008, Gosford, New South Wales

Site AU61007, Wollongong, New South Wales

Site AU61005, Fitzroy, Victoria

Site AU61006, Warrnambool, Victoria

Site BR55012, Porto Alegre, Rio Grande Do Sul

Site BR55009, Centro Passo Fundo, Not set

Site BR55008, Rio Grande Do Sul, Not set

Site BR55004, Santa Catarina, Not set

Site BR55010, Sao Paulo, Not set

Site BR55011, Sao Paulo, Not set

Site CN86001, Beijing, Not set

Site CN86008, Beijing, Not set

Site CN86014, Beijing, Not set

Site CN86026, Changchun, Not set

Site CN86009, Chongqing, Not set

Site CN86004, Guangdong, Not set

Site CN86020, Guangdong, Not set

Site CN86016, Guangzhou, Not set

Site CN86012, Harbin, Not set

Site CN86002, Hubei, Not set

Site CN86005, Jiangsu, Not set

Site CN86011, Jiangsu, Not set

Site CN86025, Jiangsu, Not set

Site CN86024, Shan XI, Not set

Site CN86023, Shandong, Not set

Site CN86006, Shanghai, Not set

Site CN86013, Shanghai, Not set

Site CN86019, Shanghai, Not set

Site CN86007, Tianjin, Not set

Site CN86022, Xinjiang, Not set

Site CN86003, Zhejiang, Not set

Site CN86018, Zhejiang, Not set

Site CN86010, Zhengzhou, Not set

Site FR33008, Besancon, Besancon Cedex

Site FR33010, Brest, Brest Cedex

Site FR33015, Caen, Cedex 5

Site FR33006, Chambray, Cedex 9

Site FR33012, Herblain, Herblain Cedex

Site FR33016, La Chaussee Saint Victor, Loir-et-Cher

Site FR33009, Nancy, Nancy Cedex

Site FR33017, Rouen, Normandy

Site FR33003, Aquitaine, Pessac

Site FR33013, Villejuif, Villejuif Cedex

Site FR33001, Bayonne Cedex, Not set

Site FR33018, Bordeaux, Not set

Site FR33002, Grenoble, Not set

Site FR33021, Nice Cedex 2, Not set

Site FR33023, Pierre Benite, Not set

Site FR33014, Plerin, Not set

Site FR33005, Pringy Cedex, Not set

Site FR33019, Roche-Sur-Yon, Not set

Site FR33007, Strasbourg, Not set

Site IR35301, Elm Park, Dublin

Site IT39006, Rozzano, Milan

Site IT39004, Candiolo, Torino

Site IT39002, Cremona, Not set

Site IT39010, Lombardia, Not set

Site IT39003, Milan, Not set

Site IT39014, Toscana, Not set

Site IT39008, Veneto, Not set

Site JP81007, Nagoya, Aichi

Site JP81001, Kashiwa, Chiba

Site JP81005, Sapporo, Hokkaido

Site JP81006, Yokohama, Kanagawa

Site JP81003, Kashihara, Nara

Site JP81011, Bunkyo-ku, Tokyo

Site JP81012, Chuo-ku, Tokyo

Site JP81014, Koto-ku, Tokyo

Site JP81013, Mitaka, Tokyo

Site JP81002, Shinjuku-ku, Tokyo

Site JP81015, Ube, Yamaguchi

Site JP81004, Fukuoka, Not set

Site JP81010, Osaka, Not set

Site JP81009, Wakayama, Not set

Site KR82005, Seongnam-Si, Gyeonggi-do

Site KR82008, Suwon-si, Gyeonggi-do

Site KR82010, Daegu, Not set

Site KR82009, Gyeonggi-do, Not set

Site KR82001, Seoul, Not set

Site KR82003, Seoul, Not set

Site KR82004, Seoul, Not set

Site KR82007, Seoul, Not set

Site KR82002, Seoul, Not set

Site KR82006, Seoul, Not set

Site MX52004, Distrito Federal, Not set

Site MX52003, San Luis Potosi, Not set

Site MX52005, Veracruz, Not set

Site ES34004, Llobregat, Barcelona

Site ES34003, Pamplona, Navarra

Site ES34010, Barcelona, Not set

Site ES34013, Barcelona, Not set

Site ES34007, Barcelona, Not set

Site ES34018, Barcelona, Not set

Site ES34021, Barcelona, Not set

Site ES34014, Caceres, Not set

Site ES34022, Cordoba, Not set

Site ES34005, Lleida, Not set

Site ES34015, Madrid, Not set

Site ES34006, Madrid, Not set

Site ES34009, Madrid, Not set

Site ES34026, Malaga, Not set

Site ES34017, Santiago de Compostela, Not set

Site TW88608, New Taipei City, Not set

Site TW88602, Taichung City, Not set

Site TW88601, Taipei City, Not set

Site TW88609, Taipei City, Not set

Site TR90004, Ankara, Not set

Site TR90006, Ankara, Not set

Site TR90003, Diyarbakir, Not set

Site TR90002, Istanbul, Not set

Site TR90001, Konya, Not set

Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

Learn More ›

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269

Recruiting

The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina

Conditions: Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma

Learn More ›

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

NCT03725436

Active Not Recruiting

This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ALRN-6924 and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm

Learn More ›

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

NCT04216472

Active Not Recruiting

This phase II trial studies how well nab-paclitaxel and alpelisib works in treating patients with triple negative breast cancer with PIK3CA or PTEN alterations that does not respond to anthracycline chemotherapy (anthrocycline refractory). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpelisib may stop the growth of tumor cells by block... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma

Learn More ›

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

NCT05775289

Active Not Recruiting

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: Henry Ford Health System, Detroit, Michigan +50 locations

Henry Ford Health System, Detroit, Michigan

Renown Regional Medical Center Hospital, Reno, Nevada

Westmead Hospital, Westmead, New South Wales

Lyell McEwin Hospital, Adelaide, South Australia

Barwon Health, Geelong, Victoria

Monash Health, Melbourne, Victoria

UZ Brussel, Brussel, Not set

Jessa Zkh (Campus Virga Jesse), Hasselt, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

AZ St Maarten Campus Leopoldstr, Mechelen, Not set

Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, Bahia

Crio - Centro Regional Integrado de Oncologia, Fortaleza, Ceará

Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul

Hospital de Clínicas de Porto Alegre X, Porto Alegre, Rio Grande Do Sul

Hospital de Cancer de Barretos, Barretos, São Paulo

Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo

Centre Leon Berard, Lyon, Not set

Hopital Cochin, Paris, Not set

Ico Rene Gauducheau, Saint Herblain, Not set

CHU de Toulouse - Hôpital Larrey, Toulouse cedex 9, Not set

Uniklinik Essen, Essen, Not set

LungenClinic Großhansdorf GmbH, Großhansdorf, Not set

Krankenhaus Martha-Maria Halle-Doelau, Halle (Saale), Not set

Thoraxklinik Heidelberg gGmbH, Heidelberg, Not set

Lungenfachklinik Immenhausen, Immenhausen, Not set

Azienda Ospedaliera San Giuseppe Moscati, Avellino, Campania

AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica, Bologna, Emilia-Romagna

Policlinico Universitario "Agostino Gemelli", Roma, Lazio

IRCCS AOU San Martino - IST, Genova, Liguria

Irccs Istituto Europeo di Oncologia (IEO), Milano, Lombardia

Asst Di Monza, Monza, Lombardia

IOV - Istituto Oncologico Veneto - IRCCS, Padova, Veneto

Pusan National University Hospital, Busan, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

ONCARE Viaducto Napoles, Ciudad de México, Mexico CITY (federal District)

AMIISTO Atencion Medica Integral Investigacion y Terapia Oncologica S.A de C.V, Ciudad de México, Mexico CITY (federal District)

Instituto Nacional de Cancerologia, Distrito Federal, Not set

Oncológico Potosino, San Luis Potosí, Not set

Institut Catala d Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona

Hospital Son Llatzer, Palma de Mallorca, Islas Baleares

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, LA Coruna

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Regional Universitario Carlos Haya, Malaga, Not set

Memorial Ankara Hastanesi, Ankara, Not set

Ankara City Hospital, Ankara, Not set

Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Not set

Medipol University Medical Faculty, Istanbul, Not set

?zmir Medical Park, Izm?r, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

NCT05207709

Active Not Recruiting

HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: Morton Plant Hospital, Clearwater, Florida +70 locations

Morton Plant Hospital, Clearwater, Florida

University of Miami, Coral Gables, Florida

Memorial Regional Hospital, Hollywood, Florida

Mount Sinai Florida, Miami, Florida

Northwestern, Chicago, Illinois

Carle Cancer Center, Urbana, Illinois

University of Kentucky, Markey Cancer Center, Lexington, Kentucky

Sinai of Baltimore, Baltimore, Maryland

Dana Faber Cancer Institute, Boston, Massachusetts

Baptist Memorial Health Care, Oxford, Mississippi

University of Nebraska Medical Center, Omaha, Nebraska

Nevada Cancer Research Foundation, Las Vegas, Nevada

NHOH, Londonderry, New Hampshire

Montefiore, Bronx, New York

Nothwell Health, New York, New York

University of North Carolina Lineberger, Chapel Hill, North Carolina

Novant Health Care, Winston-Salem, North Carolina

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Dayton Clinical Oncology, Kettering, Ohio

Legacy Good Samaritan Hospital and Medical Cente, Portland, Oregon

Providence Portland Medical Center, Portland, Oregon

The Medical University of South Carolina, Charleston, South Carolina

Upstate Carolina Medical Center, Spartanburg, South Carolina

Edwards Comprehensive Cancer Center, Huntington, Virginia

Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia

Unv. Wisconsin, Madison, Wisconsin

Hospital Senhora da Oliveira - Guimarães, Creixomil, Not set

IPO Lisboa, Lisboa, Not set

Hospital Beatriz Ângelo, Loures, Not set

Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE, Porto, Not set

Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Not set

Institut Català d' Oncologia (ICO Badalona), Badalona, Barcelona

Institut Català d'Oncologia (ICO Hospitalet), Hospitalet de Llobregat, Barcelona

Hospital General de Catalunya, Sant Cugat Del Vallès, Barcelona

Hospital Son Llàtzer, Palma de Mallorca, Illes Balears

Hospital Universitario de Canarias, Tenerife, Islas Canarias

Hospital Clínico Universitario de A Coruña, A Coruña, La Coruña

Hospital Clínico Universitario de Santiago CHUS, Santiago De Compostela, La Coruña

Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid

Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia

Hospital General Universitario de Alicante, Alicante, Not set

Hospital del Mar, Barcelona, Not set

Vall d´Hebron University Hospital, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

IOB-Institute of Oncology. Hospital Quironsalud Barcelona, Barcelona, Not set

Hospital de Basurto, Bilbao, Not set

Complejo Hospitalario San Pedro de Alcántara, Cáceres, Not set

Institut Català d' Oncologia de Girona (ICO Girona), Girona, Not set

Hospital Universitario Virgen de las Nieves, Granada, Not set

H. Clínico San Cecilio de Granada, Granada, Not set

Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas, Not set

Complejo Asistencial Universitario de León, León, Not set

Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Not set

Hospital Universitario La Princesa, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital La Paz, Madrid, Not set

Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Not set

Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Not set

Hospital Virgen de la Victoria, Malaga, Not set

Hospital Universitario Morales Meseguer, Murcia, Not set

Hospital Sant Joan de Reus, Reus, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Marqués de Valdecilla, Santander, Not set

Hospital Virgen de la Macarena, Sevilla, Not set

Hospital Quiron Salud Sagrado Corazon Sevilla, Sevilla, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Instituto Valenciano de Oncología (IVO), Valencia, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

NCT01982448

Completed

This is a phase II study randomizing patients with stage I with T1 \> 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to predict pathologic response to preoperative chemotherapy.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: University of Alabama, Birmingham, Alabama +19 locations

Conditions: Triple Negative Breast Cancer

Learn More ›

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

NCT03281369

Active Not Recruiting

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer) and esophageal cancer. Two cohorts of patients with gastric cancer have been enrolled in parallel in this study: the second-line (2L) Gastric Cancer Cohort consists of patients with... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: Mayo Clinic Cancer Center, Scottsdale, Arizona +22 locations

Mayo Clinic Cancer Center, Scottsdale, Arizona

Uni of Southern California, Los Angeles, California

UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California

Columbia University Medical Center, New York, New York

Tennessee Oncology - Nashville, Nashville, Tennessee

The University of Texas MD Anderson Cancer Center, Houston, Texas

Blacktown Hospital, Blacktown, New South Wales

Peter MacCallum Cancer Centre, Melbourne, Victoria

Rambam Health Care Campus, Haifa, Not set

Sourasky Medical Centre, Tel-Aviv, Not set

Seoul National University Bundang Hospital, Gyeonggi-do, Not set

Seoul National University Hospital (SNUH) - Medical Oncology Center, Seoul, Not set

Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center, Seoul, Not set

University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Not set

The Catholic University of Korea St. Vincent's Hospital, Suwon-si,, Not set

Universidad de Navarra - Clinica Universitaria de Navarra (CUN), Pamplona, Navarra

Hospital Universitari Vall dHebron, Barcelona, Not set

National Cheng Kung University Hospital, Tainan, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM, London, Not set

The Royal Marsden, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton, Not set

Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Learn More ›

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969

Active Not Recruiting

The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

04/23/2025

Locations: Research Site, La Jolla, California +33 locations

Research Site, La Jolla, California

Research Site, Los Angeles, California

Research Site, Orange, California

Research Site, Ventura, California

Research Site, Atlanta, Georgia

Research Site, Coeur d'Alene, Idaho

Research Site, Boston, Massachusetts

Research Site, Ann Arbor, Michigan

Research Site, Grand Rapids, Michigan

Research Site, Buffalo, New York

Research Site, New York, New York

Research Site, Portland, Oregon

Research Site, San Antonio, Texas

Research Site, Charlottesville, Virginia

Research Site, Seattle, Washington

Research Site, Madison, Wisconsin

Research Site, Barrie, Ontario

Research Site, Toronto, Ontario

Research Site, Seongnam-si, Not set

Research Site, Seongnam-Si, Not set

Research Site, Seoul, Not set

Research Site, Badalona, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Pamplona, Not set

Conditions: Locally Advanced or Metastatic Solid Tumours

Learn More ›

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

NCT06360354

Recruiting

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

04/23/2025

Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +70 locations

Comprehensive Blood and Cancer Center, Bakersfield, California

City of Hope National Medical Center, Duarte, California

University of California San Diego Moores Cancer Center, La Jolla, California

Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California

University of California Los Angeles, Santa Monica, California

Rocky Mountain Cancer Centers, Aurora, Colorado

Hartford Hospital, Hartford, Connecticut

Yale University, New Haven, Connecticut

Norwalk Hospital, Norwalk, Connecticut

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Norton Cancer Institute, Louisville, Kentucky

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Washington University, Saint Louis, Missouri

University of Nebraska, Omaha, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Memorial Sloan Kettering Cancer Center, New York, New York

Duke University, Durham, North Carolina

Cleveland Clinic Foundation, Cleveland, Ohio

United States Oncology Regulatory Affairs Corporate Office, Nashville, Tennessee

Oncology Consultants Cancer Center, Houston, Texas

US Oncology Research Investigational Products Center, Irving, Texas

University of Virginia Cancer Center, Charlottesville, Virginia

Virginia Cancer Specialists PC, Fairfax, Virginia

Northwest Medical Specialties, PLLC, Tacoma, Washington

Northwest Cancer Specialists - Vancouver, Vancouver, Washington

Chris OBrien Lifehouse, Camperdown, New South Wales

GenesisCare -North Shore Oncology, St Leonards, New South Wales

The Queen Elizabeth Hospital, Woodville South, South Australia

Austin Health, Austin Hospital, Heidelberg, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria

Epworth Healthcare, St Albans, Victoria

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Not set

Universitair Ziekenhuis Antwerpen, Edegem, Not set

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Not set

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta

Princess Margaret Cancer Centre, Toronto, Ontario

CHU de Quebec Hopital de l Enfant Jesus, Quebec, Not set

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Herlev og Gentofte Hospital, Herlev, Not set

Institut Bergonie, Bordeaux, Not set

Centre Georges Francois Leclerc, Dijon, Not set

Institut Paoli Calmettes, Marseille, Not set

Gustave Roussy, Villejuif, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Universitaetsklinikum Wuerzburg, Wuerzburg, Not set

Alexandra Hospital, Athens, Not set

Saint Luke Hospital, Thessaloniki, Not set

General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Not set

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Not set

IRCCS Istituto Clinico Humanitas, Rozzano MI, Not set

Centro Ricerche Cliniche Di Verona Societa responsabilita limitata, Verona, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa

National Cancer Center Hospital, Chuo-ku, Tokyo

Radboud Universitair Medisch Centrum, Nijmegen, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Andalucía

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital General Universitario Gregorio Maranon, Madrid, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Queen Elizabeth Hospital Birmingham, Birmingham, Not set

Sarah Cannon Research Institute UK, London, Not set

Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Learn More ›

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

NCT03096418

Recruiting

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Conditions: Breast Neoplasm Female

Learn More ›

Browse by State

Paclitaxel treatment options in Alabama

Paclitaxel treatment options in Alaska

Paclitaxel treatment options in Arizona

Paclitaxel treatment options in Arkansas

Paclitaxel treatment options in California

Paclitaxel treatment options in Colorado

Paclitaxel treatment options in Connecticut

Paclitaxel treatment options in Delaware

Paclitaxel treatment options in District of Columbia

Paclitaxel treatment options in Florida

Paclitaxel treatment options in Georgia

Paclitaxel treatment options in Hawaii

Paclitaxel treatment options in Idaho

Paclitaxel treatment options in Illinois

Paclitaxel treatment options in Indiana

Paclitaxel treatment options in Iowa

Paclitaxel treatment options in Kansas

Paclitaxel treatment options in Kentucky

Paclitaxel treatment options in Louisiana

Paclitaxel treatment options in Maine

Paclitaxel treatment options in Montana

Paclitaxel treatment options in Nebraska

Paclitaxel treatment options in Nevada

Paclitaxel treatment options in New Hampshire

Paclitaxel treatment options in New Jersey

Paclitaxel treatment options in New Mexico

Paclitaxel treatment options in New York

Paclitaxel treatment options in North Carolina

Paclitaxel treatment options in North Dakota

Paclitaxel treatment options in Ohio

Paclitaxel treatment options in Oklahoma

Paclitaxel treatment options in Oregon

Paclitaxel treatment options in Maryland

Paclitaxel treatment options in Massachusetts

Paclitaxel treatment options in Michigan

Paclitaxel treatment options in Minnesota

Paclitaxel treatment options in Mississippi

Paclitaxel treatment options in Missouri

Paclitaxel treatment options in Pennsylvania

Paclitaxel treatment options in Rhode Island

Paclitaxel treatment options in South Carolina

Paclitaxel treatment options in South Dakota

Paclitaxel treatment options in Tennessee

Paclitaxel treatment options in Texas

Paclitaxel treatment options in Utah

Paclitaxel treatment options in Vermont

Paclitaxel treatment options in Virginia

Paclitaxel treatment options in Washington

Paclitaxel treatment options in West Virginia

Paclitaxel treatment options in Wisconsin

Paclitaxel treatment options in Wyoming